Exelixis Q1 2022 revenue $356M, EPS $0.21; cabozantinib franchise $310.3M

EXELIXIS, INC.

2022-Q1 EPS reported $0.21 revenue$355,980,000

Total revenues $356.0M vs $270.2M YoY; net product revenues $310.3M vs $227.2M, driven by higher cabozantinib volume.
GAAP net income $68.6M ($0.21 diluted EPS) vs $1.6M ($0.00); non-GAAP EPS $0.26 vs $0.09.
Cabozantinib franchise growth: increased demand for CABOMETYX+OPDIVO in first-line RCC and DTC label expansion.
Cash and investments $2.0B at March 31, 2022, up from $1.9B at December 31, 2021.
Pipeline advancing: XL092 phase 3 STELLAR-303 to initiate Q2 2022; phase 1 trials of XL092, XB002, XL102 ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.